Tetrahydrocannabinol provides cardioprotection
Cardiac Research Laboratory, Felsenstein Medical Research Center, Rabin Medical Center, Petah Tiqwa, Israel
Description – Three regimens of THC administration were tested: single THC application 2h or 48h before the induction of infarct, or 3 weeks continuous treatment before MI. All protocols of THC administration were found to be beneficial. In the case of THC treatment 2h before MI, fractional shortening was elevated (37±4% vs. 42±1%, p<0.04), troponin T leakage to the blood was reduced (14±3ng/ml vs. 10±4ng/ml, p<0.008), infarct size decreased (29±4% vs. 23±4%, p<0.02), and the accumulation of neutrophils to the infarct area declined (36±10cells/field vs. 19±4cells/field, p<0.007) in THC- compared to vehicle-pretreated mice, 24h after MI. ERK1/2 phosphorylation following infarct was also inhibited by pre-treatment with THC (p<0.01).
Sigma-Aldrich report – Link – Report as of July 2016 – An ultra-low dose of tetrahydrocannabinol provides cardioprotection. | Sigma-Aldrich
NIH PubMed information – Link – Information as of July 2016 – An ultra-low dose of tetrahydrocannabinol provides cardioprotection
Science Direct Information – Link – Information as of July 2016 – An ultra-low dose of tetrahydrocannabinol provides cardioprotection